Login Register Cart 0
General Review Article

神经紧张素能系统：癌症治疗的一个目标

卷 29, 期 18, 2022

发表于: 12 January, 2022

页: [3231 - 3260] 页: 30

弟呕挨: 10.2174/0929867328666211027124328

价格: $65

摘要

背景：在过去的几年中，关于多肽参与癌症的科学兴趣有所增加。在肿瘤细胞中，多肽及其受体的过表达是已知的，并提出了治疗癌症的新的治疗靶点。神经紧张素能系统的过表达与不良预后、肿瘤大小、更高的肿瘤侵袭性、复发风险增加和对化疗药物的敏感性更差相关。目的：本综述的目的是更新有关神经紧张素能系统参与癌症的研究结果，以提出针对该系统的抗癌治疗策略。神经紧张素(NT)前体、NT及其受体(NTR)，以及神经紧张素能系统在肺、乳腺癌、前列腺、胃、结肠、肝癌和胰腺癌、胶质母细胞瘤、神经内分泌肿瘤和b细胞白血病中的作用，以及NT介导的信号通路。未来将提出一些研究思路，如调节NT前体表达的分子，饮食在肿瘤发展中的影响，NT激活的分子和信号通路，以及针对神经紧张素能系统的抗肿瘤治疗策略。结论：NT通过NTR发挥致癌（肿瘤细胞增殖、侵袭、迁移、血管生成）和抗凋亡作用，而NTR拮抗剂则抑制这些作用。NTR表达可作为诊断工具/治疗靶点，而NTR拮抗剂作为抗肿瘤药物可作为治疗NTR过表达肿瘤的一种治疗策略。

关键词: 神经紧张素，神经紧张素受体拮抗剂，肿瘤，肺、乳腺、前列腺、胃肠、肝脏，信号通路。

« Previous Next »
[1]
Mattiuzzi, C.; Lippi, G. Current cancer epidemiology. J. Epidemiol. Glob. Health, 2019, 9(4), 217-222.
[http://dx.doi.org/10.2991/jegh.k.191008.001] [PMID: 31854162]
[2]
Muñoz, M.; Coveñas, R. Involvement of substance P and the NK-1 receptor in human pathology. Amino Acids, 2014, 46(7), 1727-1750.
[http://dx.doi.org/10.1007/s00726-014-1736-9] [PMID: 24705689]
[3]
Kastin, A.J. Handbook of Biologically Active Peptides, 2nd ed; Academic Press: Amsterdam, 2013.
[4]
Zhao, M.; Wang, T.; Liu, Q.; Cummins, S. Copy number alteration of neuropeptides and receptors in multiple cancers. Sci. Rep., 2017, 7(1), 4598.
[http://dx.doi.org/10.1038/s41598-017-04832-0] [PMID: 28676692]
[5]
Kasprzak, A.; Adamek, A. The neuropeptide system and colorectal cancer liver metastases: mechanisms and management. Int. J. Mol. Sci., 2020, 21(10), 3494.
[http://dx.doi.org/10.3390/ijms21103494] [PMID: 32429087]
[6]
Colucci, R.; Blandizzi, C.; Ghisu, N.; Florio, T.; Del Tacca, M. Somatostatin inhibits colon cancer cell growth through cyclooxygenase-2 downregulation. Br. J. Pharmacol., 2008, 155(2), 198-209.
[http://dx.doi.org/10.1038/bjp.2008.268] [PMID: 18587421]
[7]
Bugni, J.M.; Rabadi, L.A.; Jubbal, K.; Karagiannides, I.; Lawson, G.; Pothoulakis, C. The neurotensin receptor-1 promotes tumor development in a sporadic but not an inflammation-associated mouse model of colon cancer. Int. J. Cancer, 2012, 130(8), 1798-1805.
[http://dx.doi.org/10.1002/ijc.26208] [PMID: 21630261]
[8]
Evers, B.M. Neurotensin and growth of normal and neoplastic tissues. Peptides, 2006, 27(10), 2424-2433.
[http://dx.doi.org/10.1016/j.peptides.2006.01.028] [PMID: 16904238]
[9]
Bugni, J.M.; Pothoulakis, C. Neurotensin. In: Handbook of Biologically Active Peptides; Kastin, A.J., Ed.; Academic Press: Amsterdam, 2013; pp. 1265-1270.
[10]
Wu, Z.; Fournel, L.; Stadler, N.; Liu, J.; Boullier, A.; Hoyeau, N.; Fléjou, J.F.; Duchatelle, V.; Djebrani-Oussedik, N.; Agopiantz, M.; Ségal-Bendirdjian, E.; Gompel, A.; Alifano, M.; Melander, O.; Trédaniel, J.; Forgez, P. Modulation of lung cancer cell plasticity and heterogeneity with the restoration of cisplatin sensitivity by neurotensin antibody. Cancer Lett., 2019, 444, 147-161.
[http://dx.doi.org/10.1016/j.canlet.2018.12.007] [PMID: 30583074]
[11]
Carraway, R.E.; Plona, A.M. Involvement of neurotensin in cancer growth: evidence, mechanisms and development of diagnostic tools. Peptides, 2006, 27(10), 2445-2460.
[http://dx.doi.org/10.1016/j.peptides.2006.04.030] [PMID: 16887236]
[12]
Mouritzen, M.V.; Abourayale, S.; Ejaz, R.; Ardon, C.B.; Carvalho, E.; Dalgaard, L.T.; Roursgaard, M.; Jenssen, H. Neurotensin, substance P, and insulin enhance cell migration. J. Pept. Sci., 2018, 24(7), e3093.
[http://dx.doi.org/10.1002/psc.3093] [PMID: 29938867]
[13]
Bakirtzi, K.; Law, I.K.; Xue, X.; Iliopoulos, D.; Shah, Y.M.; Pothoulakis, C. Neurotensin promotes the development of colitis and intestinal angiogenesis via Hif-1α-miR-210 signaling. J. Immunol., 2016, 196(10), 4311-4321.
[http://dx.doi.org/10.4049/jimmunol.1501443] [PMID: 27076683]
[14]
Bakirtzi, K.; West, G.; Fiocchi, C.; Law, I.K.; Iliopoulos, D.; Pothoulakis, C. The neurotensin-HIF-1α-VEGFα axis orchestrates hypoxia, colonic inflammation, and intestinal angiogenesis. Am. J. Pathol., 2014, 184(12), 3405-3414.
[http://dx.doi.org/10.1016/j.ajpath.2014.08.015] [PMID: 25307345]
[15]
Campbell, G.E.; Bender, H.R.; Parker, G.A.; Curry, T.E., Jr; Duffy, D.M. Neurotensin: A novel mediator of ovulation? FASEB J., 2021, 35(4), e21481.
[http://dx.doi.org/10.1096/fj.202002547RR] [PMID: 33710668]
[16]
Christou, N.; Blondy, S.; David, V.; Verdier, M.; Lalloué, F.; Jauberteau, M.O.; Mathonnet, M.; Perraud, A. Neurotensin pathway in digestive cancers and clinical applications: An overview. Cell Death Dis., 2020, 11(12), 1027.
[http://dx.doi.org/10.1038/s41419-020-03245-8] [PMID: 33268796]
[17]
Gully, D.; Canton, M.; Boigegrain, R.; Jeanjean, F.; Molimard, J.C.; Poncelet, M.; Gueudet, C.; Heaulme, M.; Leyris, R.; Brouard, A. Biochemical and pharmacological profile of a potent and selective nonpeptide antagonist of the neurotensin receptor. Proc. Natl. Acad. Sci. USA, 1993, 90(1), 65-69.
[http://dx.doi.org/10.1073/pnas.90.1.65] [PMID: 8380498]
[18]
Bakirtzi, K.; Hatziapostolou, M.; Karagiannides, I.; Polytarchou, C.; Jaeger, S.; Bakirtzi, K.; Hatziapostolou, M.; Karagiannides, I.; Polytarchou, C.; Jaeger, S.; Iliopoulos, D.; Pothoulakis, C. Neurotensin signaling activates microRNAs-21 and -155 and Akt, promotes tumor growth in mice, and is increased in human colon tumors. Gastroenterology, 2011, 141(5), 1749-61.
[http://dx.doi.org/10.1053/j.gastro.2011.07.038] [PMID: 21806946]
[19]
Zhu, S.; Tian, H.; Niu, X.; Wang, J.; Li, X.; Jiang, N.; Wen, S.; Chen, X.; Ren, S.; Xu, C.; Chang, C.; Flores-Morales, A.; Shang, Z.; Sun, Y.; Niu, Y. Neurotensin and its receptors mediate neuroendocrine transdifferentiation in prostate cancer. Oncogene, 2019, 38(24), 4875-4884.
[http://dx.doi.org/10.1038/s41388-019-0750-5] [PMID: 30770901]
[20]
Dong, Z.; Wang, X.; Zhao, Q.; Townsend, C.M., Jr; Evers, B.M. DNA methylation contributes to expression of the human neurotensin/neuromedin N gene. Am. J. Physiol., 1998, 274(3), G535-G543.
[PMID: 9530155]
[21]
Vincent, J.P.; Mazella, J.; Kitabgi, P. Neurotensin and neurotensin receptors. Trends Pharmacol. Sci., 1999, 20(7), 302-309.
[http://dx.doi.org/10.1016/S0165-6147(99)01357-7] [PMID: 10390649]
[22]
Dobner, P.R.; Carraway, R.E. Neurotensin/Neuromedin N. In: Handbook of Biologically Active Peptides; Kastin, A.J., Ed.; Academic Press: Amsterdam, 2013; pp. 875-882.
[23]
Cuber, J.C.; Herrmann, C.; Kitabgi, P.; Bosshard, A.; Bernard, C.; De Nadai, F.; Chayvialle, J.A. Neuromedin-N is not released with neurotensin from rat ileum. Endocrinology, 1990, 126(3), 1584-1592.
[http://dx.doi.org/10.1210/endo-126-3-1584] [PMID: 2307120]
[24]
Kitabgi, P.; De Nadai, F.; Cuber, J.C.; Dubuc, I.; Nouel, D.; Costentin, J. Calcium-dependent release of neuromedin N and neurotensin from mouse hypothalamus. Neuropeptides, 1990, 15(2), 111-114.
[http://dx.doi.org/10.1016/0143-4179(90)90047-3] [PMID: 2080018]
[25]
Carraway, R.E.; Mitra, S.P.; Spaulding, G. Posttranslational processing of the neurotensin/neuromedin-N precursor. Ann. N. Y. Acad. Sci., 1992, 668, 1-16.
[http://dx.doi.org/10.1111/j.1749-6632.1992.tb27335.x] [PMID: 1463268]
[26]
Kitabgi, P.; De Nadai, F.; Rovère, C.; Bidard, J.N. Biosynthesis, maturation, release, and degradation of neurotensin and neuromedin N. Ann. N. Y. Acad. Sci., 1992, 668, 30-42.
[http://dx.doi.org/10.1111/j.1749-6632.1992.tb27337.x] [PMID: 1463273]
[27]
Seidah, N.G.; Chrétien, M.; Day, R. The family of subtilisin/kexin like pro-protein and pro-hormone convertases: divergent or shared functions. Biochimie, 1994, 76(3-4), 197-209.
[http://dx.doi.org/10.1016/0300-9084(94)90147-3] [PMID: 7819324]
[28]
Rovère, C.; Barbero, P.; Kitabgi, P. Evidence that PC2 is the endogenous pro-neurotensin convertase in rMTC 6-23 cells and that PC1- and PC2-transfected PC12 cells differentially process pro-neurotensin. J. Biol. Chem., 1996, 271(19), 11368-11375.
[http://dx.doi.org/10.1074/jbc.271.19.11368] [PMID: 8626691]
[29]
Barbero, P.; Rovère, C.; De Bie, I.; Seidah, N.; Beaudet, A.; Kitabgi, P. PC5-A-mediated processing of pro-neurotensin in early compartments of the regulated secretory pathway of PC5-transfected PC12 cells. J. Biol. Chem., 1998, 273(39), 25339-25346.
[http://dx.doi.org/10.1074/jbc.273.39.25339] [PMID: 9738000]
[30]
Vivoli, M.; Lindberg, I. Prohormone Convertase 1/3. In: Handbook of Biologically Active Peptides; Academic Press: Amsterdam, 2013; pp. 1789-1796.
[31]
Vivoli, M.; Lindberg, I. Prohormone Convertase 2. In: Handbook of Biologically Active Peptides; Academic Press: Amsterdam, 2013; pp. 1797-1802.
[32]
Seidah, N.G. Proprotein Convertase Furin and Proprotein Convertase PC5/6. In: Handbook of Biologically Active Peptides; Academic Press: Amsterdam, 2013; pp. 1803-1811.
[33]
Rovère, C.; Barbero, P.; Maoret, J.J.; Laburthe, M.; Kitabgi, P. Pro-neurotensin/neuromedin N expression and processing in human colon cancer cell lines. Biochem. Biophys. Res. Commun., 1998, 246(1), 155-159.
[http://dx.doi.org/10.1006/bbrc.1998.8506] [PMID: 9600085]
[34]
Bidard, J.N.; de Nadai, F.; Rovere, C.; Moinier, D.; Laur, J.; Martinez, J.; Cuber, J.C.; Kitabgi, P. Immunological and biochemical characterization of processing products from the neurotensin/neuromedin N precursor in the rat medullary thyroid carcinoma 6-23 cell line. Biochem. J., 1993, 291(Pt 1), 225-233.
[http://dx.doi.org/10.1042/bj2910225] [PMID: 8471039]
[35]
Carraway, R.E.; Mitra, S.P.; Joyce, T.J. Tissue-specific processing of neurotensin/neuromedin-N precursor in cat. Regul. Pept., 1993, 43(1-2), 97-106.
[http://dx.doi.org/10.1016/0167-0115(93)90412-2] [PMID: 8426913]
[36]
Evers, B.M.; Beauchamp, R.D.; Ishizuka, J.; Townsend, C.M., Jr; Alam, T.; Papaconstantinou, J.; Thompson, J.C. Posttranscriptional regulation of neurotensin in the gut. Surgery, 1991, 110(2), 247-252.
[PMID: 1858034]
[37]
Evers, B.M. Endocrine gene neurotensin: molecular mechanisms and a model of intestinal differentiation. World J. Surg., 2002, 26(7), 799-805.
[http://dx.doi.org/10.1007/s00268-002-4055-3] [PMID: 11960215]
[38]
Evers, B.M.; Rajaraman, S.; Chung, D.H.; Townsend, C.M., Jr; Wang, X.; Graves, K.; Thompson, J.C. Developmental expression of the neurotensin gene in the rat liver. Ann. Surg., 1993, 218(2), 183-188.
[http://dx.doi.org/10.1097/00000658-199308000-00010] [PMID: 8342998]
[39]
Reinecke, M. Neurotensin. Immunohistochemical localization in central and peripheral nervous system and in endocrine cells and its functional role as neurotransmitter and endocrine hormone. Prog. Histochem. Cytochem., 1985, 16(1), 1-172.
[PMID: 2859633]
[40]
Sánchez, M.L.; Vecino, E.; Coveñas, R. Distribution of neurotensin and somatostatin-28 (1-12) in the minipig brainstem. Anat. Histol. Embryol., 2016, 45(4), 260-276.
[http://dx.doi.org/10.1111/ahe.12194] [PMID: 26250798]
[41]
Carraway, R.; Leeman, S.E. Characterization of radioimmunoassayable neurotensin in the rat. Its differential distribution in the central nervous system, small intestine, and stomach. J. Biol. Chem., 1976, 251(22), 7045-7052.
[http://dx.doi.org/10.1016/S0021-9258(17)32938-1] [PMID: 993203]
[42]
Feurle, G.E.; Müller, B.; Rix, E. Neurotensin induces hyperplasia of the pancreas and growth of the gastric antrum in rats. Gut, 1987, 28(S1)(Suppl.), 19-23.
[http://dx.doi.org/10.1136/gut.28.Suppl.19] [PMID: 3692307]
[43]
Wood, J.G.; Hoang, H.D.; Bussjaeger, L.J.; Solomon, T.E. Neurotensin stimulates growth of small intestine in rats. Am. J. Physiol., 1988, 255(6 Pt 1), G813-G817.
[PMID: 3202174]
[44]
Evers, B.M.; Izukura, M.; Chung, D.H.; Parekh, D.; Yoshinaga, K.; Greeley, G.H., Jr; Uchida, T.; Townsend, C.M., Jr; Thompson, J.C. Neurotensin stimulates growth of colonic mucosa in young and aged rats. Gastroenterology, 1992, 103(1), 86-91.
[http://dx.doi.org/10.1016/0016-5085(92)91099-P] [PMID: 1612361]
[45]
Coppola, T.; Béraud-Dufour, S.; Antoine, A.; Vincent, J.P.; Mazella, J. Neurotensin protects pancreatic beta cells from apoptosis. Int. J. Biochem. Cell Biol., 2008, 40(10), 2296-2302.
[http://dx.doi.org/10.1016/j.biocel.2008.03.015] [PMID: 18456542]
[46]
Schroeder, L.E.; Leinninger, G.M. Role of central neurotensin in regulating feeding: implications for the development and treatment of body weight disorders. Biochim. Biophys. Acta Mol. Basis Dis., 2018, 1864(3), 900-916.
[http://dx.doi.org/10.1016/j.bbadis.2017.12.036] [PMID: 29288794]
[47]
Demeule, M.; Beaudet, N.; Régina, A.; Besserer-Offroy, É.; Murza, A.; Tétreault, P.; Belleville, K.; Ché, C.; Larocque, A.; Thiot, C.; Béliveau, R.; Longpré, J.M.; Marsault, É.; Leduc, R.; Lachowicz, J.E.; Gonias, S.L.; Castaigne, J.P.; Sarret, P. Conjugation of a brain-penetrant peptide with neurotensin provides antinociceptive properties. J. Clin. Invest., 2014, 124(3), 1199-1213.
[http://dx.doi.org/10.1172/JCI70647] [PMID: 24531547]
[48]
Cui, H.; Cai, F.; Belsham, D.D. Anorexigenic hormones leptin, insulin, and alpha-melanocyte-stimulating hormone directly induce neurotensin (NT) gene expression in novel NT-expressing cell models. J. Neurosci., 2005, 25(41), 9497-9506.
[http://dx.doi.org/10.1523/JNEUROSCI.2269-05.2005] [PMID: 16221860]
[49]
Lee, M.R.; Hinton, D.J.; Song, J.Y.; Lee, K.W.; Choo, C.; Johng, H.; Unal, S.S.; Richelson, E.; Choi, D.S. Neurotensin receptor type 1 regulates ethanol intoxication and consumption in mice. Pharmacol. Biochem. Behav., 2010, 95(2), 235-241.
[http://dx.doi.org/10.1016/j.pbb.2010.01.012] [PMID: 20122953]
[50]
Blackburn, A.M.; Fletcher, D.R.; Bloom, S.R.; Christofides, N.D.; Long, R.G.; Fitzpatrick, M.L.; Baron, J.H. Effect of neurotensin on gastric function in man. Lancet, 1980, 1(8176), 987-989.
[http://dx.doi.org/10.1016/S0140-6736(80)91434-8] [PMID: 6103384]
[51]
Mustain, W.C.; Rychahou, P.G.; Evers, B.M. The role of neurotensin in physiologic and pathologic processes. Curr. Opin. Endocrinol. Diabetes Obes., 2011, 18(1), 75-82.
[http://dx.doi.org/10.1097/MED.0b013e3283419052] [PMID: 21124211]
[52]
Cáceda, R.; Kinkead, B.; Nemeroff, C.B. Neurotensin: role in psychiatric and neurological diseases. Peptides, 2006, 27(10), 2385-2404.
[http://dx.doi.org/10.1016/j.peptides.2006.04.024] [PMID: 16891042]
[53]
Brun, P.; Mastrotto, C.; Beggiao, E.; Stefani, A.; Barzon, L.; Sturniolo, G.C.; Palù, G.; Castagliuolo, I. Neuropeptide neurotensin stimulates intestinal wound healing following chronic intestinal inflammation. Am. J. Physiol. Gastrointest. Liver Physiol., 2005, 288(4), G621-G629.
[http://dx.doi.org/10.1152/ajpgi.00140.2004] [PMID: 15764810]
[54]
Binder, E.B.; Kinkead, B.; Owens, M.J.; Nemeroff, C.B. Neurotensin and dopamine interactions. Pharmacol. Rev., 2001, 53(4), 453-486.
[PMID: 11734615]
[55]
St-Gelais, F.; Legault, M.; Bourque, M.J.; Rompré, P.P.; Trudeau, L.E. Role of calcium in neurotensin-evoked enhancement in firing in mesencephalic dopamine neurons. J. Neurosci., 2004, 24(10), 2566-2574.
[http://dx.doi.org/10.1523/JNEUROSCI.5376-03.2004] [PMID: 15014132]
[56]
Ferraro, L.; Tomasini, M.C.; Fernandez, M.; Bebe, B.W.; O’Connor, W.T.; Fuxe, K.; Glennon, J.C.; Tanganelli, S.; Antonelli, T. Nigral neurotensin receptor regulation of nigral glutamate and nigroventral thalamic GABA transmission: a dual-probe microdialysis study in intact conscious rat brain. Neuroscience, 2001, 102(1), 113-120.
[http://dx.doi.org/10.1016/S0306-4522(00)00448-6] [PMID: 11226674]
[57]
Buhler, A.V.; Choi, J.; Proudfit, H.K.; Gebhart, G.F. Neurotensin activation of the NTR1 on spinally-projecting serotonergic neurons in the rostral ventromedial medulla is antinociceptive. Pain, 2005, 114(1-2), 285-294.
[http://dx.doi.org/10.1016/j.pain.2004.12.031] [PMID: 15733655]
[58]
Wenk, G.L.; Markowska, A.L.; Olton, D.S. Basal forebrain lesions and memory: Alterations in neurotensin, not acetylcholine, may cause amnesia. Behav. Neurosci., 1989, 103(4), 765-769.
[http://dx.doi.org/10.1037/0735-7044.103.4.765] [PMID: 2669837]
[59]
Lénárd, L.; László, K.; Kertes, E.; Ollmann, T.; Péczely, L.; Kovács, A.; Kállai, V.; Zagorácz, O.; Gálosi, R.; Karádi, Z. Substance P and neurotensin in the limbic system: Their roles in reinforcement and memory consolidation. Neurosci. Biobehav. Rev., 2018, 85, 1-20.
[http://dx.doi.org/10.1016/j.neubiorev.2017.09.003] [PMID: 28887225]
[60]
Rostène, W.H.; Alexander, M.J. Neurotensin and neuroendocrine regulation. Front. Neuroendocrinol., 1997, 18(2), 115-173.
[http://dx.doi.org/10.1006/frne.1996.0146] [PMID: 9101258]
[61]
Rökaeus, A.; Fried, G.; Lundberg, J.M. Occurrence, storage and release of neurotensin-like immunoreactivity from the adrenal gland. Acta Physiol. Scand., 1984, 120(3), 373-380.
[http://dx.doi.org/10.1111/j.1748-1716.1984.tb07397.x] [PMID: 6741572]
[62]
Rock, S.; Li, X.; Song, J.; Townsend, C.M., Jr; Weiss, H.L.; Rychahou, P.; Gao, T.; Li, J.; Evers, B.M. Kinase suppressor of Ras 1 and Exo70 promote fatty acid-stimulated neurotensin secretion through ERK1/2 signaling. PLoS One, 2019, 14(3), e0211134.
[http://dx.doi.org/10.1371/journal.pone.0211134] [PMID: 30917119]
[63]
Li, J.; Song, J.; Zaytseva, Y.Y.; Liu, Y.; Rychahou, P.; Jiang, K.; Starr, M.E.; Kim, J.T.; Harris, J.W.; Yiannikouris, F.B.; Katz, W.S.; Nilsson, P.M.; Orho-Melander, M.; Chen, J.; Zhu, H.; Fahrenholz, T.; Higashi, R.M.; Gao, T.; Morris, A.J.; Cassis, L.A.; Fan, T.W.; Weiss, H.L.; Dobner, P.R.; Melander, O.; Jia, J.; Evers, B.M. An obligatory role for neurotensin in high-fat-diet-induced obesity. Nature, 2016, 533(7603), 411-415.
[http://dx.doi.org/10.1038/nature17662] [PMID: 27193687]
[64]
Barber, D.L.; Cacace, A.M.; Raucci, D.T.; Ganz, M.B. Fatty acids stereospecifically stimulate neurotensin release and increase [Ca2+]i in enteric endocrine cells. Am. J. Physiol., 1991, 261(3 Pt 1), G497-G503.
[PMID: 1887896]
[65]
Zhao, D.; Pothoulakis, C. Effects of NT on gastrointestinal motility and secretion, and role in intestinal inflammation. Peptides, 2006, 27(10), 2434-2444.
[http://dx.doi.org/10.1016/j.peptides.2005.12.016] [PMID: 16872719]
[66]
Iyer, M.R.; Kunos, G. Therapeutic approaches targeting the neurotensin receptors. Expert Opin. Ther. Pat., 2021, 31(5), 361-386.
[http://dx.doi.org/10.1080/13543776.2021.1866539] [PMID: 33393392]
[67]
Fredriksson, R.; Lagerström, M.C.; Lundin, L.G.; Schiöth, H.B. The G-protein-coupled receptors in the human genome form five main families. Phylogenetic analysis, paralogon groups, and fingerprints. Mol. Pharmacol., 2003, 63(6), 1256-1272.
[http://dx.doi.org/10.1124/mol.63.6.1256] [PMID: 12761335]
[68]
Pelaprat, D. Interactions between neurotensin receptors and G proteins. Peptides, 2006, 27(10), 2476-2487.
[http://dx.doi.org/10.1016/j.peptides.2006.04.027] [PMID: 16919370]
[69]
Zsürger, N.; Mazella, J.; Vincent, J.P. Solubilization and purification of a high affinity neurotensin receptor from newborn human brain. Brain Res., 1994, 639(2), 245-252.
[http://dx.doi.org/10.1016/0006-8993(94)91737-X] [PMID: 8205478]
[70]
Tanaka, K.; Masu, M.; Nakanishi, S. Structure and functional expression of the cloned rat neurotensin receptor. Neuron, 1990, 4(6), 847-854.
[http://dx.doi.org/10.1016/0896-6273(90)90137-5] [PMID: 1694443]
[71]
Chalon, P.; Vita, N.; Kaghad, M.; Guillemot, M.; Bonnin, J.; Delpech, B.; Le Fur, G.; Ferrara, P.; Caput, D. Molecular cloning of a levocabastine-sensitive neurotensin binding site. FEBS Lett., 1996, 386(2-3), 91-94.
[http://dx.doi.org/10.1016/0014-5793(96)00397-3] [PMID: 8647296]
[72]
Dubuc, I.; Costentin, J.; Terranova, J.P.; Barnouin, M.C.; Soubrié, P.; Le Fur, G.; Rostène, W.; Kitabgi, P. The nonpeptide neurotensin antagonist, SR 48692, used as a tool to reveal putative neurotensin receptor subtypes. Br. J. Pharmacol., 1994, 112(2), 352-354.
[http://dx.doi.org/10.1111/j.1476-5381.1994.tb13077.x] [PMID: 8075852]
[73]
Mazella, J.; Botto, J.M.; Guillemare, E.; Coppola, T.; Sarret, P.; Vincent, J.P. Structure, functional expression, and cerebral localization of the levocabastine-sensitive neurotensin/neuromedin N receptor from mouse brain. J. Neurosci., 1996, 16(18), 5613-5620.
[http://dx.doi.org/10.1523/JNEUROSCI.16-18-05613.1996] [PMID: 8795617]
[74]
Gully, D.; Labeeuw, B.; Boigegrain, R.; Oury-Donat, F.; Bachy, A.; Poncelet, M.; Steinberg, R.; Suaud-Chagny, M.F.; Santucci, V.; Vita, N.; Pecceu, F.; Labbé-Jullié, C.; Kitabgi, P.; Soubrié, P.; Le Fur, G.; Maffrand, J.P. Biochemical and pharmacological activities of SR 142948A, a new potent neurotensin receptor antagonist. J. Pharmacol. Exp. Ther., 1997, 280(2), 802-812.
[PMID: 9023294]
[75]
Vita, N.; Oury-Donat, F.; Chalon, P.; Guillemot, M.; Kaghad, M.; Bachy, A.; Thurneyssen, O.; García, S.; Poinot-Chazel, C.; Casellas, P.; Keane, P.; Le Fur, G.; Maffrand, J.P.; Soubrie, P.; Caput, D.; Ferrara, P. Neurotensin is an antagonist of the human neurotensin NT2 receptor expressed in Chinese hamster ovary cells. Eur. J. Pharmacol., 1998, 360(2-3), 265-272.
[http://dx.doi.org/10.1016/S0014-2999(98)00678-5] [PMID: 9851594]
[76]
White, J.F.; Grodnitzky, J.; Louis, J.M.; Trinh, L.B.; Shiloach, J.; Gutierrez, J.; Northup, J.K.; Grisshammer, R. Dimerization of the class A G protein-coupled neurotensin receptor NTS1 alters G protein interaction. Proc. Natl. Acad. Sci. USA, 2007, 104(29), 12199-12204.
[http://dx.doi.org/10.1073/pnas.0705312104] [PMID: 17620610]
[77]
Hwang, J.R.; Baek, M.W.; Sim, J.; Choi, H.S.; Han, J.M.; Kim, Y.L.; Hwang, J.I.; Kwon, H.B.; Beaudet, N.; Sarret, P.; Seong, J.Y. Intermolecular cross-talk between NTR1 and NTR2 neurotensin receptor promotes intracellular sequestration and functional inhibition of NTR1 receptors. Biochem. Biophys. Res. Commun., 2010, 391(1), 1007-1013.
[http://dx.doi.org/10.1016/j.bbrc.2009.12.007] [PMID: 19968961]
[78]
Petersen, C.M.; Nielsen, M.S.; Nykjaer, A.; Jacobsen, L.; Tommerup, N.; Rasmussen, H.H.; Roigaard, H.; Gliemann, J.; Madsen, P.; Moestrup, S.K. Molecular identification of a novel candidate sorting receptor purified from human brain by receptor-associated protein affinity chromatography. J. Biol. Chem., 1997, 272(6), 3599-3605.
[http://dx.doi.org/10.1074/jbc.272.6.3599] [PMID: 9013611]
[79]
Mazella, J.; Zsürger, N.; Navarro, V.; Chabry, J.; Kaghad, M.; Caput, D.; Ferrara, P.; Vita, N.; Gully, D.; Maffrand, J.P.; Vincent, J.P. The 100-kDa neurotensin receptor is gp95/sortilin, a non-G-protein-coupled receptor. J. Biol. Chem., 1998, 273(41), 26273-26276.
[http://dx.doi.org/10.1074/jbc.273.41.26273] [PMID: 9756851]
[80]
Talbot, H.; Saada, S.; Naves, T.; Gallet, P.F.; Fauchais, A.L.; Jauberteau, M.O. Regulatory roles of sortilin and SorLA in immune-related processes. Front. Pharmacol., 2019, 9, 1507.
[http://dx.doi.org/10.3389/fphar.2018.01507] [PMID: 30666202]
[81]
Quistgaard, E.M.; Madsen, P.; Grøftehauge, M.K.; Nissen, P.; Petersen, C.M.; Thirup, S.S. Ligands bind to Sortilin in the tunnel of a ten-bladed beta-propeller domain. Nat. Struct. Mol. Biol., 2009, 16(1), 96-98.
[http://dx.doi.org/10.1038/nsmb.1543] [PMID: 19122660]
[82]
Quistgaard, E.M.; Grøftehauge, M.K.; Madsen, P.; Pallesen, L.T.; Christensen, B.; Sørensen, E.S.; Nissen, P.; Petersen, C.M.; Thirup, S.S. Revisiting the structure of the Vps10 domain of human sortilin and its interaction with neurotensin. Protein Sci., 2014, 23(9), 1291-1300.
[http://dx.doi.org/10.1002/pro.2512] [PMID: 24985322]
[83]
Nykjaer, A.; Lee, R.; Teng, K.K.; Jansen, P.; Madsen, P.; Nielsen, M.S.; Jacobsen, C.; Kliemannel, M.; Schwarz, E.; Willnow, T.E.; Hempstead, B.L.; Petersen, C.M. Sortilin is essential for proNGF-induced neuronal cell death. Nature, 2004, 427(6977), 843-848.
[http://dx.doi.org/10.1038/nature02319] [PMID: 14985763]
[84]
Teng, H.K.; Teng, K.K.; Lee, R.; Wright, S.; Tevar, S.; Almeida, R.D.; Kermani, P.; Torkin, R.; Chen, Z.Y.; Lee, F.S.; Kraemer, R.T.; Nykjaer, A.; Hempstead, B.L. ProBDNF induces neuronal apoptosis via activation of a receptor complex of p75NTR and sortilin. J. Neurosci., 2005, 25(22), 5455-5463.
[http://dx.doi.org/10.1523/JNEUROSCI.5123-04.2005] [PMID: 15930396]
[85]
Yano, H.; Torkin, R.; Martin, L.A.; Chao, M.V.; Teng, K.K. Proneurotrophin-3 is a neuronal apoptotic ligand: evidence for retrograde-directed cell killing. J. Neurosci., 2009, 29(47), 14790-14802.
[http://dx.doi.org/10.1523/JNEUROSCI.2059-09.2009] [PMID: 19940174]
[86]
Blondy, S.; Christou, N.; David, V.; Verdier, M.; Jauberteau, M.O.; Mathonnet, M.; Perraud, A. Neurotrophins and their involvement in digestive cancers. Cell Death Dis., 2019, 10(2), 123.
[http://dx.doi.org/10.1038/s41419-019-1385-8] [PMID: 30741921]
[87]
Massa, F.; Devader, C.; Béraud-Dufour, S.; Brau, F.; Coppola, T.; Mazella, J. Focal adhesion kinase dependent activation of the PI3 kinase pathway by the functional soluble form of neurotensin receptor-3 in HT29 cells. Int. J. Biochem. Cell Biol., 2013, 45(5), 952-959.
[http://dx.doi.org/10.1016/j.biocel.2013.01.020] [PMID: 23395631]
[88]
Massa, F.; Devader, C.; Lacas-Gervais, S.; Béraud-Dufour, S.; Coppola, T.; Mazella, J. Impairement of HT29 cancer cells cohesion by the soluble form of neurotensin receptor-3. Genes Cancer, 2014, 5(7-8), 240-249.
[http://dx.doi.org/10.18632/genesandcancer.22] [PMID: 25221642]
[89]
Leloup, N.; Lössl, P.; Meijer, D.H.; Brennich, M.; Heck, A.J.R.; Thies-Weesie, D.M.E.; Janssen, B.J.C. Low pH-induced conformational change and dimerization of sortilin triggers endocytosed ligand release. Nat. Commun., 2017, 8(1), 1708.
[http://dx.doi.org/10.1038/s41467-017-01485-5] [PMID: 29167428]
[90]
Devader, C.; Béraud-Dufour, S.; Coppola, T.; Mazella, J. The anti-apoptotic role of neurotensin. Cells, 2013, 2(1), 124-135.
[http://dx.doi.org/10.3390/cells2010124] [PMID: 24709648]
[91]
Wilson, C.M.; Naves, T.; Al Akhrass, H.; Vincent, F.; Melloni, B.; Bonnaud, F.; Lalloué, F.; Jauberteau, M.O. A new role under sortilin’s belt in cancer. Commun. Integr. Biol., 2016, 9(1), e1130192.
[http://dx.doi.org/10.1080/19420889.2015.1130192] [PMID: 27066187]
[92]
Martin, S.; Navarro, V.; Vincent, J.P.; Mazella, J. Neurotensin receptor-1 and -3 complex modulates the cellular signaling of neurotensin in the HT29 cell line. Gastroenterology, 2002, 123(4), 1135-1143.
[http://dx.doi.org/10.1053/gast.2002.36000] [PMID: 12360476]
[93]
Li, J.H.; Sicard, F.; Salam, M.A.; Baek, M.; LePrince, J.; Vaudry, H.; Kim, K.; Kwon, H.B.; Seong, J.Y. Molecular cloning and functional characterization of a type-I neurotensin receptor (NTR) and a novel NTR from the bullfrog brain. J. Mol. Endocrinol., 2005, 34(3), 793-807.
[http://dx.doi.org/10.1677/jme.1.01709] [PMID: 15956348]
[94]
Nakaizumi, A.; Uehara, H.; Baba, M.; Iishi, H.; Tatsuta, M. Enhancement by neurotensin of hepatocarcinogenesis by N-nitrosomorpholine in Sprague-Dawley rats. Cancer Lett., 1996, 110(1-2), 57-61.
[http://dx.doi.org/10.1016/S0304-3835(96)04466-7] [PMID: 9018081]
[95]
Gerber, M. Background review paper on total fat, fatty acid intake and cancers. Ann. Nutr. Metab., 2009, 55(1-3), 140-161.
[http://dx.doi.org/10.1159/000229000] [PMID: 19752540]
[96]
Moody, T.W. Peptide hormones and lung cancer. Panminerva Med., 2006, 48(1), 19-26.
[PMID: 16633328]
[97]
Alifano, M.; Souazé, F.; Dupouy, S.; Camilleri-Broët, S.; Younes, M.; Ahmed-Zaïd, S.M.; Takahashi, T.; Cancellieri, A.; Damiani, S.; Boaron, M.; Broët, P.; Miller, L.D.; Gespach, C.; Regnard, J.F.; Forgez, P. Neurotensin receptor 1 determines the outcome of non-small cell lung cancer. Clin. Cancer Res., 2010, 16(17), 4401-4410.
[http://dx.doi.org/10.1158/1078-0432.CCR-10-0659] [PMID: 20810387]
[98]
Younes, M.; Wu, Z.; Dupouy, S.; Lupo, A.M.; Mourra, N.; Takahashi, T.; Fléjou, J.F.; Trédaniel, J.; Régnard, J.F.; Damotte, D.; Alifano, M.; Forgez, P. Neurotensin (NTS) and its receptor (NTSR1) causes EGFR, HER2 and HER3 over-expression and their autocrine/paracrine activation in lung tumors, confirming responsiveness to erlotinib. Oncotarget, 2014, 5(18), 8252-8269.
[http://dx.doi.org/10.18632/oncotarget.1633] [PMID: 25249545]
[99]
Wilson, C.M.; Naves, T.; Vincent, F.; Melloni, B.; Bonnaud, F.; Lalloué, F.; Jauberteau, M.O. Sortilin mediates the release and transfer of exosomes in concert with two tyrosine kinase receptors. J. Cell Sci., 2014, 127(Pt 18), 3983-3997.
[http://dx.doi.org/10.1242/jcs.149336] [PMID: 25037567]
[100]
Al-Akhrass, H.; Naves, T.; Vincent, F.; Magnaudeix, A.; Durand, K.; Bertin, F.; Melloni, B.; Jauberteau, M.O.; Lalloué, F. Sortilin limits EGFR signaling by promoting its internalization in lung cancer. Nat. Commun., 2017, 8(1), 1182.
[http://dx.doi.org/10.1038/s41467-017-01172-5] [PMID: 29084952]
[101]
Zhu, M.C.; Xiong, P.; Li, G.L.; Zhu, M. Could lung cancer exosomes induce apoptosis of natural killer cells through the p75NTR-proNGF-sortilin axis? Med. Hypotheses, 2017, 108, 151-153.
[http://dx.doi.org/10.1016/j.mehy.2017.09.003] [PMID: 29055389]
[102]
Dupouy, S.; Viardot-Foucault, V.; Alifano, M.; Souazé, F.; Plu-Bureau, G.; Chaouat, M.; Lavaur, A.; Hugol, D.; Gespach, C.; Gompel, A.; Forgez, P. The neurotensin receptor-1 pathway contributes to human ductal breast cancer progression. PLoS One, 2009, 4(1), e4223.
[http://dx.doi.org/10.1371/journal.pone.0004223] [PMID: 19156213]
[103]
Cross, A.S.; Azzopardi, J.G.; Krausz, T.; van Noorden, S.; Polak, J.M. A morphological and immunocytochemical study of a distinctive variant of ductal carcinoma in-situ of the breast. Histopathology, 1985, 9(1), 21-37.
[http://dx.doi.org/10.1111/j.1365-2559.1985.tb02968.x] [PMID: 2579885]
[104]
Souazé, F.; Dupouy, S.; Viardot-Foucault, V.; Bruyneel, E.; Attoub, S.; Gespach, C.; Gompel, A.; Forgez, P. Expression of neurotensin and NT1 receptor in human breast cancer: a potential role in tumor progression. Cancer Res., 2006, 66(12), 6243-6249.
[http://dx.doi.org/10.1158/0008-5472.CAN-06-0450] [PMID: 16778199]
[105]
Roselli, S.; Pundavela, J.; Demont, Y.; Faulkner, S.; Keene, S.; Attia, J.; Jiang, C.C.; Zhang, X.D.; Walker, M.M.; Hondermarck, H. Sortilin is associated with breast cancer aggressiveness and contributes to tumor cell adhesion and invasion. Oncotarget, 2015, 6(12), 10473-10486.
[http://dx.doi.org/10.18632/oncotarget.3401] [PMID: 25871389]
[106]
Demont, Y.; Corbet, C.; Page, A.; Ataman-Önal, Y.; Choquet-Kastylevsky, G.; Fliniaux, I.; Le Bourhis, X.; Toillon, R.A.; Bradshaw, R.A.; Hondermarck, H. Pro-nerve growth factor induces autocrine stimulation of breast cancer cell invasion through tropomyosin-related kinase A (TrkA) and sortilin protein. J. Biol. Chem., 2012, 287(3), 1923-1931.
[http://dx.doi.org/10.1074/jbc.M110.211714] [PMID: 22128158]
[107]
Castillo-Rodríguez, R.A.; Arango-Rodríguez, M.L.; Escobedo, L.; Hernández-Baltazar, D.; Gompel, A.; Forgez, P.; Martínez-Fong, D. Suicide HSVtk gene delivery by neurotensin-polyplex nanoparticles via the bloodstream and GCV Treatment specifically inhibit the growth of human MDA-MB-231 triple negative breast cancer tumors xenografted in athymic mice. PLoS One, 2014, 9(5), e97151.
[http://dx.doi.org/10.1371/journal.pone.0097151] [PMID: 24824754]
[108]
Dupouy, S.; Doan, V.K.; Wu, Z.; Mourra, N.; Liu, J.; De Wever, O.; Llorca, F.P.; Cayre, A.; Kouchkar, A.; Gompel, A.; Forgez, P. Activation of EGFR, HER2 and HER3 by neurotensin/neurotensin receptor 1 renders breast tumors aggressive yet highly responsive to lapatinib and metformin in mice. Oncotarget, 2014, 5(18), 8235-8251.
[http://dx.doi.org/10.18632/oncotarget.1632] [PMID: 25249538]
[109]
Sehgal, I.; Powers, S.; Huntley, B.; Powis, G.; Pittelkow, M.; Maihle, N.J. Neurotensin is an autocrine trophic factor stimulated by androgen withdrawal in human prostate cancer. Proc. Natl. Acad. Sci. USA, 1994, 91(11), 4673-4677.
[http://dx.doi.org/10.1073/pnas.91.11.4673] [PMID: 8197117]
[110]
Moody, T.W.; Mayr, C.A.; Gillespie, T.J.; Davis, T.P. Neurotensin is metabolized by endogenous proteases in prostate cancer cell lines. Peptides, 1998, 19(2), 253-258.
[http://dx.doi.org/10.1016/S0196-9781(97)00306-9] [PMID: 9493857]
[111]
Dal Farra, C.; Sarret, P.; Navarro, V.; Botto, J.M.; Mazella, J.; Vincent, J.P. Involvement of the neurotensin receptor subtype NTR3 in the growth effect of neurotensin on cancer cell lines. Int. J. Cancer, 2001, 92(4), 503-509.
[http://dx.doi.org/10.1002/ijc.1225] [PMID: 11304684]
[112]
Valerie, N.C.; Casarez, E.V.; Dasilva, J.O.; Dunlap-Brown, M.E.; Parsons, S.J.; Amorino, G.P.; Dziegielewski, J. Inhibition of neurotensin receptor 1 selectively sensitizes prostate cancer to ionizing radiation. Cancer Res., 2011, 71(21), 6817-6826.
[http://dx.doi.org/10.1158/0008-5472.CAN-11-1646] [PMID: 21903767]
[113]
Morgat, C.; Chastel, A.; Molinie, V.; Schollhammer, R.; Macgrogan, G.; Vélasco, V.; Malavaud, B.; Fernandez, P.; Hindié, E. Neurotensin receptor-1 expression in human prostate cancer: a pilot study on primary tumors and lymph node metastases. Int. J. Mol. Sci., 2019, 20(7), 1721.
[http://dx.doi.org/10.3390/ijms20071721] [PMID: 30959962]
[114]
Swift, S.L.; Burns, J.E.; Maitland, N.J. Altered expression of neurotensin receptors is associated with the differentiation state of prostate cancer. Cancer Res., 2010, 70(1), 347-356.
[http://dx.doi.org/10.1158/0008-5472.CAN-09-1252] [PMID: 20048080]
[115]
Tanimoto, R.; Morcavallo, A.; Terracciano, M.; Xu, S.Q.; Stefanello, M.; Buraschi, S.; Lu, K.G.; Bagley, D.H.; Gomella, L.G.; Scotlandi, K.; Belfiore, A.; Iozzo, R.V.; Morrione, A. Sortilin regulates progranulin action in castration-resistant prostate cancer cells. Endocrinology, 2015, 156(1), 58-70.
[http://dx.doi.org/10.1210/en.2014-1590] [PMID: 25365768]
[116]
Tanimoto, R.; Palladino, C.; Xu, S.Q.; Buraschi, S.; Neill, T.; Gomella, L.G.; Peiper, S.C.; Belfiore, A.; Iozzo, R.V.; Morrione, A. The perlecan-interacting growth factor progranulin regulates ubiquitination, sorting, and lysosomal degradation of sortilin. Matrix Biol., 2017, 64, 27-39.
[http://dx.doi.org/10.1016/j.matbio.2017.04.001] [PMID: 28433812]
[117]
Geer, S.; Reigl, U.; Maschauer, S.; Ritt, P.; Gmeiner, P.; Grill, E.; Prante, O. The neurotensin receptor subtype 1 as target for radiotherapy in prostate cancer. J. Labelled Comp. Radiopharm., 2017, 60, S21.
[118]
Xiangya Hospital of Central South University. A Study of 18F-AlF-NOTA-Neurotensin PET/CT for Imaging Prostate Cancer. NCT03516045 2018.
[119]
Zhou, Z.; Xie, J.; Cai, Y.; Yang, S.; Chen, Y.; Wu, H. The significance of NTR1 expression and its correlation with β-catenin and EGFR in gastric cancer. Diagn. Pathol., 2015, 10, 128.
[http://dx.doi.org/10.1186/s13000-015-0356-3] [PMID: 26215716]
[120]
Dong, Z.; Wang, X.; Evers, B.M. Site-specific DNA methylation contributes to neurotensin/neuromedin N expression in colon cancers. Am. J. Physiol. Gastrointest. Liver Physiol., 2000, 279(6), G1139-G1147.
[http://dx.doi.org/10.1152/ajpgi.2000.279.6.G1139] [PMID: 11093935]
[121]
Maoret, J.J.; Pospaï, D.; Rouyer-Fessard, C.; Couvineau, A.; Laboisse, C.; Voisin, T.; Laburthe, M. Neurotensin receptor and its mRNA are expressed in many human colon cancer cell lines but not in normal colonic epithelium: binding studies and RT-PCR experiments. Biochem. Biophys. Res. Commun., 1994, 203(1), 465-471.
[http://dx.doi.org/10.1006/bbrc.1994.2205] [PMID: 7521165]
[122]
Kim, J.T.; Weiss, H.L.; Evers, B.M. Diverse expression patterns and tumorigenic role of neurotensin signaling components in colorectal cancer cells. Int. J. Oncol., 2017, 50(6), 2200-2206.
[http://dx.doi.org/10.3892/ijo.2017.3990] [PMID: 28498396]
[123]
Gui, X.; Guzman, G.; Dobner, P.R.; Kadkol, S.S. Increased neurotensin receptor-1 expression during progression of colonic adenocarcinoma. Peptides, 2008, 29(9), 1609-1615.
[http://dx.doi.org/10.1016/j.peptides.2008.04.014] [PMID: 18541341]
[124]
Kontovounisios, C.; Qiu, S.; Rasheed, S.; Darzi, A.; Tekkis, P. The role of neurotensin as a novel biomarker in the endoscopic screening of high-risk population for developing colorectal neoplasia. Updates Surg., 2017, 69(3), 397-402.
[http://dx.doi.org/10.1007/s13304-017-0464-6] [PMID: 28560510]
[125]
Yoshinaga, K.; Evers, B.M.; Izukura, M.; Parekh, D.; Uchida, T.; Townsend, C.M., Jr; Thompson, J.C. Neurotensin stimulates growth of colon cancer. Surg. Oncol., 1992, 1(2), 127-134.
[http://dx.doi.org/10.1016/0960-7404(92)90025-G] [PMID: 1341243]
[126]
Maoret, J.J.; Anini, Y.; Rouyer-Fessard, C.; Gully, D.; Laburthe, M. Neurotensin and a non-peptide neurotensin receptor antagonist control human colon cancer cell growth in cell culture and in cells xenografted into nude mice. Int. J. Cancer, 1999, 80(3), 448-454.
[http://dx.doi.org/10.1002/(SICI)1097-0215(19990129)80:3<448:AID-IJC19>3.0.CO;2-N] [PMID: 9935189]
[127]
Akil, H.; Perraud, A.; Mélin, C.; Jauberteau, M.O.; Mathonnet, M. Fine-tuning roles of endogenous brain-derived neurotrophic factor, TrkB and sortilin in colorectal cancer cell survival. PLoS One, 2011, 6(9), e25097.
[http://dx.doi.org/10.1371/journal.pone.0025097] [PMID: 21966426]
[128]
Ye, Y.; Long, X.; Zhang, L.; Chen, J.; Liu, P.; Li, H.; Wei, F.; Yu, W.; Ren, X.; Yu, J. NTS/NTR1 co-expression enhances epithelial-to-mesenchymal transition and promotes tumor metastasis by activating the Wnt/β-catenin signaling pathway in hepatocellular carcinoma. Oncotarget, 2016, 7(43), 70303-70322.
[http://dx.doi.org/10.18632/oncotarget.11854] [PMID: 27611941]
[129]
Wu, Z.; Galmiche, A.; Liu, J.; Stadler, N.; Wendum, D.; Segal-Bendirdjian, E.; Paradis, V.; Forgez, P. Neurotensin regulation induces overexpression and activation of EGFR in HCC and restores response to erlotinib and sorafenib. Cancer Lett., 2017, 388, 73-84.
[http://dx.doi.org/10.1016/j.canlet.2016.11.032] [PMID: 27914862]
[130]
Collier, N.A.; Weinbren, K.; Bloom, S.R.; Lee, Y.C.; Hodgson, H.J.; Blumgart, L.H. Neurotensin secretion by fibrolamellar carcinoma of the liver. Lancet, 1984, 1(8376), 538-540.
[http://dx.doi.org/10.1016/S0140-6736(84)90934-6] [PMID: 6199633]
[131]
Tang, K.H.; Ma, S.; Lee, T.K.; Chan, Y.P.; Kwan, P.S.; Tong, C.M.; Ng, I.O.; Man, K.; To, K.F.; Lai, P.B.; Lo, C.M.; Guan, X.Y.; Chan, K.W. CD133(+) liver tumor-initiating cells promote tumor angiogenesis, growth, and self-renewal through neurotensin/interleukin-8/CXCL1 signaling. Hepatology, 2012, 55(3), 807-820.
[http://dx.doi.org/10.1002/hep.24739] [PMID: 21994122]
[132]
Yu, J.; Ren, X.; Chen, Y.; Liu, P.; Wei, X.; Li, H.; Ying, G.; Chen, K.; Winkler, H.; Hao, X. Dysfunctional activation of neurotensin/IL-8 pathway in hepatocellular carcinoma is associated with increased inflammatory response in microenvironment, more epithelial mesenchymal transition in cancer and worse prognosis in patients. PLoS One, 2013, 8(2), e56069.
[http://dx.doi.org/10.1371/journal.pone.0056069] [PMID: 23418512]
[133]
Feurle, G.E.; Helmstaedter, V.; Tischbirek, K.; Carraway, R.; Forssmann, W.G.; Grube, D.; Röher, H.D. A multihormonal tumor of the pancreas producing neurotensin. Dig. Dis. Sci., 1981, 26(12), 1125-1133.
[http://dx.doi.org/10.1007/BF01295980] [PMID: 7307861]
[134]
Reubi, J.C.; Waser, B.; Friess, H.; Büchler, M.; Laissue, J. Neurotensin receptors: A new marker for human ductal pancreatic adenocarcinoma. Gut, 1998, 42(4), 546-550.
[http://dx.doi.org/10.1136/gut.42.4.546] [PMID: 9616318]
[135]
Yin, X.; Wang, M.; Wang, H.; Deng, H.; He, T.; Tan, Y.; Zhu, Z.; Wu, Z.; Hu, S.; Li, Z. Evaluation of neurotensin receptor 1 as a potential imaging target in pancreatic ductal adenocarcinoma. Amino Acids, 2017, 49(8), 1325-1335.
[http://dx.doi.org/10.1007/s00726-017-2430-5] [PMID: 28536844]
[136]
Körner, M.; Waser, B.; Strobel, O.; Büchler, M.; Reubi, J.C. Neurotensin receptors in pancreatic ductal carcinomas. EJNMMI Res., 2015, 5, 17.
[http://dx.doi.org/10.1186/s13550-015-0094-2] [PMID: 25859423]
[137]
Ehlers, R.A.; Kim, Sh.; Zhang, Y.; Ethridge, R.T.; Murrilo, C.; Hellmich, M.R.; Evans, D.B.; Townsend, C.M., Jr; Mark Evers, B. Gut peptide receptor expression in human pancreatic cancers. Ann. Surg., 2000, 231(6), 838-848.
[http://dx.doi.org/10.1097/00000658-200006000-00008] [PMID: 10816627]
[138]
Ishizuka, J.; Townsend, C.M., Jr; Thompson, J.C. Neurotensin regulates growth of human pancreatic cancer. Ann. Surg., 1993, 217(5), 439-445.
[http://dx.doi.org/10.1097/00000658-199305010-00003] [PMID: 8387763]
[139]
Iwase, K.; Evers, B.M.; Hellmich, M.R.; Kim, H.J.; Higashide, S.; Gully, D.; Thompson, J.C.; Townsend, C.M., Jr Inhibition of neurotensin-induced pancreatic carcinoma growth by a nonpeptide neurotensin receptor antagonist, SR48692. Cancer, 1997, 79(9), 1787-1793.
[http://dx.doi.org/10.1002/(SICI)1097-0142(19970501)79:9<1787:AID-CNCR22>3.0.CO;2-T] [PMID: 9128997]
[140]
Mijatovic, T.; Gailly, P.; Mathieu, V.; De Nève, N.; Yeaton, P.; Kiss, R.; Decaestecker, C. Neurotensin is a versatile modulator of in vitro human pancreatic ductal adenocarcinoma cell (PDAC) migration. Cell. Oncol., 2007, 29(4), 315-326.
[PMID: 17641415]
[141]
Wang, M.; Zhang, H.; Wang, H.; Feng, H.; Deng, H.; Wu, Z.; Lu, H.; Li, Z. Development of [18F] AlF-NOTA-NT as PET agents of neurotensin receptor-1 positive pancreatic cancer. Mol. Pharm., 2018, 15(8), 3093-3100.
[http://dx.doi.org/10.1021/acs.molpharmaceut.8b00192] [PMID: 29889537]
[142]
Baum, R.P.; Singh, A.; Schuchardt, C.; Kulkarni, H.R.; Klette, I.; Wiessalla, S.; Osterkamp, F.; Reineke, U.; Smerling, C. 177Lu-3BP-227 for neurotensin receptor 1-targeted therapy of metastatic pancreatic adenocarcinoma: first clinical results. J. Nucl. Med., 2018, 59(5), 809-814.
[http://dx.doi.org/10.2967/jnumed.117.193847] [PMID: 29025990]
[143]
Ipsen. Study to evaluate the safety and activity (including distribution) of 177Lu-3BP-227 in subjects with solid tumours expressing neurotensin receptor type 1. NCT03525392 2018.
[144]
Dong, Z.; Lei, Q.; Yang, R.; Zhu, S.; Ke, X.X.; Yang, L.; Cui, H.; Yi, L. Inhibition of neurotensin receptor 1 induces intrinsic apoptosis via let-7a-3p/Bcl-w axis in glioblastoma. Br. J. Cancer, 2017, 116(12), 1572-1584.
[http://dx.doi.org/10.1038/bjc.2017.126] [PMID: 28494471]
[145]
Ayala-Sarmiento, A.E.; Martínez-Fong, D.; Segovia, J. The internalization of neurotensin by the low-affinity neurotensin receptors (NTSR2 and vNTSR2) activates ERK 1/2 in glioma cells and allows neurotensin-polyplex transfection of tGAS1. Cell. Mol. Neurobiol., 2015, 35(6), 785-795.
[http://dx.doi.org/10.1007/s10571-015-0172-z] [PMID: 25772140]
[146]
Yang, W.; Wu, P.F.; Ma, J.X.; Liao, M.J.; Wang, X.H.; Xu, L.S.; Xu, M.H.; Yi, L. Sortilin promotes glioblastoma invasion and mesenchymal transition through GSK-3β/β-catenin/twist pathway. Cell Death Dis., 2019, 10(3), 208.
[http://dx.doi.org/10.1038/s41419-019-1449-9] [PMID: 30814514]
[147]
Korbecki, J.; Gutowska, I.; Kojder, I.; Jeżewski, D.; Goschorska, M.; Łukomska, A.; Lubkowska, A.; Chlubek, D.; Baranowska-Bosiacka, I. New extracellular factors in glioblastoma multiforme development: neurotensin, growth differentiation factor-15, sphingosine-1-phosphate and cytomegalovirus infection. Oncotarget, 2018, 9(6), 7219-7270.
[http://dx.doi.org/10.18632/oncotarget.24102] [PMID: 29467963]
[148]
Xiong, J.; Zhou, L.; Yang, M.; Lim, Y.; Zhu, Y.H.; Fu, D.L.; Li, Z.W.; Zhong, J.H.; Xiao, Z.C.; Zhou, X.F. ProBDNF and its receptors are upregulated in glioma and inhibit the growth of glioma cells in vitro. Neuro-oncol., 2013, 15(8), 990-1007.
[http://dx.doi.org/10.1093/neuonc/not039] [PMID: 23576602]
[149]
Kim, J.T.; Li, J.; Song, J.; Lee, E.Y.; Weiss, H.L.; Townsend, C.M., Jr; Evers, B.M. Differential expression and tumorigenic function of neurotensin receptor 1 in neuroendocrine tumor cells. Oncotarget, 2015, 6(29), 26960-26970.
[http://dx.doi.org/10.18632/oncotarget.4745] [PMID: 26298774]
[150]
Saada, S.; Marget, P.; Fauchais, A.L.; Lise, M.C.; Chemin, G.; Sindou, P.; Martel, C.; Delpy, L.; Vidal, E.; Jaccard, A.; Troutaud, D.; Lalloué, F.; Jauberteau, M.O. Differential expression of neurotensin and specific receptors, NTSR1 and NTSR2, in normal and malignant human B lymphocytes. J. Immunol., 2012, 189(11), 5293-5303.
[http://dx.doi.org/10.4049/jimmunol.1102937] [PMID: 23109725]
[151]
Abbaci, A.; Talbot, H.; Saada, S.; Gachard, N.; Abraham, J.; Jaccard, A.; Bordessoule, D.; Fauchais, A.L.; Naves, T.; Jauberteau, M.O. Neurotensin receptor type 2 protects B-cell chronic lymphocytic leukemia cells from apoptosis. Oncogene, 2018, 37(6), 756-767.
[http://dx.doi.org/10.1038/onc.2017.365] [PMID: 29059151]
[152]
Skrzydelski, D.; Lhiaubet, A.M.; Lebeau, A.; Forgez, P.; Yamada, M.; Hermans, E.; Rostene, W.; Pelaprat, D. Differential involvement of intracellular domains of the rat NTS1 neurotensin receptor in coupling to G proteins: A molecular basis for agonist-directed trafficking of receptor stimulus. Mol. Pharmacol., 2003, 64(2), 421-429.
[http://dx.doi.org/10.1124/mol.64.2.421] [PMID: 12869647]
[153]
Kitabgi, P. Neurotensin and neuromedin N are differentially processed from a common precursor by prohormone convertases in tissues and cell lines. Results Probl. Cell Differ., 2010, 50, 85-96.
[PMID: 19862492]
[154]
Zhao, D.; Bakirtzi, K.; Zhan, Y.; Zeng, H.; Koon, H.W.; Pothoulakis, C. Insulin-like growth factor-1 receptor transactivation modulates the inflammatory and proliferative responses of neurotensin in human colonic epithelial cells. J. Biol. Chem., 2011, 286(8), 6092-6099.
[http://dx.doi.org/10.1074/jbc.M110.192534] [PMID: 21212273]
[155]
Zhao, D.; Zhan, Y.; Koon, H.W.; Zeng, H.; Keates, S.; Moyer, M.P.; Pothoulakis, C. Metalloproteinase-dependent transforming growth factor-alpha release mediates neurotensin-stimulated MAP kinase activation in human colonic epithelial cells. J. Biol. Chem., 2004, 279(42), 43547-43554.
[http://dx.doi.org/10.1074/jbc.M401453200] [PMID: 15247267]
[156]
Ehlers, R.A.; Zhang, Y.; Hellmich, M.R.; Evers, B.M. Neurotensin-mediated activation of MAPK pathways and AP-1 binding in the human pancreatic cancer cell line, MIA PaCa-2. Biochem. Biophys. Res. Commun., 2000, 269(3), 704-708.
[http://dx.doi.org/10.1006/bbrc.2000.2335] [PMID: 10720480]
[157]
Zhao, D.; Zhan, Y.; Zeng, H.; Koon, H.W.; Moyer, M.P.; Pothoulakis, C. Neurotensin stimulates interleukin-8 expression through modulation of I kappa B alpha phosphorylation and p65 transcriptional activity: involvement of protein kinase C alpha. Mol. Pharmacol., 2005, 67(6), 2025-2031.
[http://dx.doi.org/10.1124/mol.104.010801] [PMID: 15755906]
[158]
Amorino, G.P.; Deeble, P.D.; Parsons, S.J. Neurotensin stimulates mitogenesis of prostate cancer cells through a novel c-Src/Stat5b pathway. Oncogene, 2007, 26(5), 745-756.
[http://dx.doi.org/10.1038/sj.onc.1209814] [PMID: 16862179]
[159]
DaSilva, J.O.; Amorino, G.P.; Casarez, E.V.; Pemberton, B.; Parsons, S.J. Neuroendocrine-derived peptides promote prostate cancer cell survival through activation of IGF-1R signaling. Prostate, 2013, 73(8), 801-812.
[http://dx.doi.org/10.1002/pros.22624] [PMID: 23192379]
[160]
Hassan, S.; Dobner, P.R.; Carraway, R.E. Involvement of MAP-kinase, PI3-kinase and EGF-receptor in the stimulatory effect of Neurotensin on DNA synthesis in PC3 cells. Regul. Pept., 2004, 120(1-3), 155-166.
[http://dx.doi.org/10.1016/j.regpep.2004.03.004] [PMID: 15177934]
[161]
Moody, T.W.; Lee, L.; Ramos-Alvarez, I.; Jensen, R.T. Neurotensin receptors regulate transactivation of the EGFR and HER2 in a reactive oxygen species-dependent manner. Eur. J. Pharmacol., 2019, 865, 172735.
[http://dx.doi.org/10.1016/j.ejphar.2019.172735] [PMID: 31614143]
[162]
Riehle, K.J.; Kenerson, H.L.; Riggle, K.M.; Turnham, R.; Sullivan, K.; Bauer, R.; Scott, J.D.; Yeung, R.S. Neurotensin as a source of cyclic AMP and co-mitogen in fibrolamellar hepatocellular carcinoma. Oncotarget, 2019, 10(49), 5092-5102.
[http://dx.doi.org/10.18632/oncotarget.27149] [PMID: 31489118]
[163]
Müller, K.M.; Tveteraas, I.H.; Aasrum, M.; Ødegård, J.; Dawood, M.; Dajani, O.; Christoffersen, T.; Sandnes, D.L. Role of protein kinase C and epidermal growth factor receptor signalling in growth stimulation by neurotensin in colon carcinoma cells. BMC Cancer, 2011, 11, 421.
[http://dx.doi.org/10.1186/1471-2407-11-421] [PMID: 21961726]
[164]
Souazé, F.; Viardot-Foucault, V.; Roullet, N.; Toy-Miou-Leong, M.; Gompel, A.; Bruyneel, E.; Comperat, E.; Faux, M.C.; Mareel, M.; Rostène, W.; Fléjou, J.F.; Gespach, C.; Forgez, P. Neurotensin receptor 1 gene activation by the Tcf/beta-catenin pathway is an early event in human colonic adenomas. Carcinogenesis, 2006, 27(4), 708-716.
[http://dx.doi.org/10.1093/carcin/bgi269] [PMID: 16299383]
[165]
Fodde, R.; Smits, R.; Clevers, H. APC, signal transduction and genetic instability in colorectal cancer. Nat. Rev. Cancer, 2001, 1(1), 55-67.
[http://dx.doi.org/10.1038/35094067] [PMID: 11900252]
[166]
Gross, K.J.; Pothoulakis, C. Role of neuropeptides in inflammatory bowel disease. Inflamm. Bowel Dis., 2007, 13(7), 918-932.
[http://dx.doi.org/10.1002/ibd.20129] [PMID: 17343284]
[167]
Koon, H.W.; Kim, Y.S.; Xu, H.; Kumar, A.; Zhao, D.; Karagiannides, I.; Dobner, P.R.; Pothoulakis, C. Neurotensin induces IL-6 secretion in mouse preadipocytes and adipose tissues during 2,4,6,-trinitrobenzensulphonic acid-induced colitis. Proc. Natl. Acad. Sci. USA, 2009, 106(21), 8766-8771.
[http://dx.doi.org/10.1073/pnas.0903499106] [PMID: 19443690]
[168]
Navarro, V.; Vincent, J.P.; Mazella, J. Shedding of the luminal domain of the neurotensin receptor-3/sortilin in the HT29 cell line. Biochem. Biophys. Res. Commun., 2002, 298(5), 760-764.
[http://dx.doi.org/10.1016/S0006-291X(02)02564-0] [PMID: 12419319]
[169]
Massa, F.; Tormo, A.; Béraud-Dufour, S.; Coppola, T.; Mazella, J. Neurotensin-induced Erk1/2 phosphorylation and growth of human colonic cancer cells are independent from growth factors receptors activation. Biochem. Biophys. Res. Commun., 2011, 414(1), 118-122.
[http://dx.doi.org/10.1016/j.bbrc.2011.09.034] [PMID: 21945442]
[170]
Béraud-Dufour, S.; Devader, C.; Massa, F.; Roulot, M.; Coppola, T.; Mazella, J. Focal adhesion kinase-dependent role of the soluble form of neurotensin receptor-3/sortilin in colorectal cancer cell dissociation. Int. J. Mol. Sci., 2016, 17(11), 1860.
[http://dx.doi.org/10.3390/ijms17111860] [PMID: 27834811]
[171]
Muñoz, M.; González-Ortega, A.; Rosso, M.; Robles-Frías, M.J.; Carranza, A.; Salinas-Martín, M.V.; Coveñas, R. The substance P/neurokinin-1 receptor system in lung cancer: focus on the antitumor action of neurokinin-1 receptor antagonists. Peptides, 2012, 38(2), 318-325.
[http://dx.doi.org/10.1016/j.peptides.2012.09.024] [PMID: 23026680]
[172]
Zhang, Y.; Zhu, S.; Yi, L.; Liu, Y.; Cui, H. Neurotensin receptor1 antagonist SR48692 reduces proliferation by inducing apoptosis and cell cycle arrest in melanoma cells. Mol. Cell. Biochem., 2014, 389(1-2), 1-8.
[http://dx.doi.org/10.1007/s11010-013-1920-3] [PMID: 24357116]
[173]
Blondy, S.; Talbot, H.; Saada, S.; Christou, N.; Battu, S.; Pannequin, J.; Jauberteau, M.O.; Lalloué, F.; Verdier, M.; Mathonnet, M.; Perraud, A. Overexpression of sortilin is associated with 5-FU resistance and poor prognosis in colorectal cancer. J. Cell. Mol. Med., 2021, 25(1), 47-60.
[http://dx.doi.org/10.1111/jcmm.15752] [PMID: 33325631]
[174]
Reubi, J.C.; Waser, B.; Schaer, J.C.; Laissue, J.A. Neurotensin receptors in human neoplasms: high incidence in Ewing’s sarcomas. Int. J. Cancer, 1999, 82(2), 213-218.
[http://dx.doi.org/10.1002/(SICI)1097-0215(19990719)82:2<213:AID-IJC11>3.0.CO;2-8] [PMID: 10389755]
[175]
Iwase, K.; Evers, B.M.; Hellmich, M.R.; Kim, H.J.; Higashide, S.; Gully, D.; Townsend, C.M. Jr Indirect inhibitory effect of a neurotensin receptor antagonist on human colon cancer (LoVo) growth. Surg. Oncol., 1996, 5(5-6), 245-251.
[http://dx.doi.org/10.1016/S0960-7404(96)80028-4] [PMID: 9129137]

Rights & Permissions Print Cite
Article Metrics
20
1
© 2024 Bentham Science Publishers | Privacy Policy